2. Search Result
Search Result
Results for "

diabete,

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

1

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0401
    Tolbutamide
    Maximum Cited Publications
    8 Publications Verification

    		 Na+/K+ ATPase Metabolic Disease Cancer
    Tolbutamide is an orally active KATP inhibitor. Tolbutamide inhibits cell proliferation, stimulates exocytosis of glucagon and reduces fetal lethality of mice. Tolbutamide can be used in the research of diabete .
    Tolbutamide
  • HY-112185
    Orforglipron
    1 Publications Verification

    LY3502970; GLP-1 receptor agonist 1

    		 GCGR Metabolic Disease
    Orforglipron (LY3502970) (Compound 67) is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorates the type 2 diabete .
    Orforglipron
  • HY-151591
    SPAA-52

    		Phosphatase Metabolic Disease
    SPAA-52 is an orally active, competitive and reversible low-molecular-weight protein tyrosine phosphatase (LMW-PTP) inhibitor (IC50=4 nM, Ki=1.2 nM). SPAA-52 can be used in diabete research .
    SPAA-52
  • HY-B0401R
    Tolbutamide (Standard)

    		Reference Standards Na+/K+ ATPase Metabolic Disease Cancer
    Tolbutamide (Standard) is the analytical standard of Tolbutamide. This product is intended for research and analytical applications. Tolbutamide is an orally active KATP inhibitor. Tolbutamide inhibits cell proliferation, stimulates exocytosis of glucagon and reduces fetal lethality of mice. Tolbutamide can be used in the research of diabete .
    Tolbutamide (Standard)
  • HY-148190
    Sheng Gelieting

    CGT-8012

    		 Dipeptidyl Peptidase Endocrinology
    Sheng Gelieting (CGT-8012) is a dipeptidy peptidase-IV enzyme (DP-IV) inhibitor. Sheng Gelieting has great DP-IV inhibition activity with an IC50 value of 87 nM. Sheng Gelieting can be used for curing or preventing diseases relevant to the dipeptidy peptidase-IV enzyme, such as the diabetes, particularly the II-type diabete .
    Sheng Gelieting
  • HY-112185A
    Orforglipron hemicalcium hydrate
    1 Publications Verification

    LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate

    		 GCGR Metabolic Disease
    Orforglipron hemicalcium hydrate (LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate) is the calcium salt hydrate form of Orforglipron (HY-112185). Orforglipron is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorating the type 2 diabete .
    Orforglipron hemicalcium hydrate
  • HY-19859
    AMG-222 tosylate

    		Dipeptidyl Peptidase Metabolic Disease
    AMG-222 (tosylate) is a DPP-IV inhibitor that can be used in the research of type II diabete .
    AMG-222 tosylate
  • HY-P4843
    Gastric Inhibitory Polypeptide (6-30) amide (human)

    		GCGR Metabolic Disease
    Gastric Inhibitory Polypeptide (6-30) amide (human) is an incretin hormone. Gastric Inhibitory Polypeptide (6-30) amide (human) can be used for the research of diabete .
    Gastric Inhibitory Polypeptide (6-30) amide (human)
  • HY-114834
    AHL-157

    		Drug Derivative Metabolic Disease
    AHL-157 is a fibrate hypolipidemic agent. AHL-157 can decrease triglyceride, cholesterol, and blood sugar. AHL-157 can be used for the research of metabolic disease, such as hyperlipidemia and diabete .
    AHL-157
  • HY-170588
    α-Glucosidase-IN-78

    		Glycosidase Metabolic Disease
    α-Glucosidase-IN-78 (Compound 12m) is an inhibitor for α-glucosidase with a reversible, competitive IC50 6.0 μM. α-Glucosidase-IN-78 can be used in research of diabete for its hypoglycemic property .
    α-Glucosidase-IN-78
  • HY-168329
    TGR5 agonist 7

    		G protein-coupled Bile Acid Receptor 1 Metabolic Disease
    TGR5 agonist 7 (Compound 22-Na) is a gut-restricted, orally active agonist for G protein-coupled bile acid receptor TGR5 (GPBAR1 or GPR131) with an EC50 < 1 μM. TGR5 agonist 7 exhibits blood glucose lowering effect in mouse model, and can be used in diabete research .
    TGR5 agonist 7
  • HY-170582
    PTP1B-IN-29

    		Phosphatase Metabolic Disease
    PTP1B-IN-29 (Compound A2B5) is an inhibitor for phosphatase, that inhibits protein tyrosine phosphatase 1B (PTP1B), TCPTP and λPPase with IC50s of 1.27 μM, 4.38 μM and 8.79 μM, respectively. PTP1B-IN-29 can be used in research of diabete and obesity .
    PTP1B-IN-29
  • HY-170409
    BNN27

    		Trk Receptor Apoptosis Neurological Disease Inflammation/Immunology
    BNN27 is the agonist for TrkA receptor and p75NTR receptor, that exhibits neurotrophic and anti-apoptotic effects. BNN27 increases the levels of glutamate, GABA, and glutamine in the rat hippocampus and prefrontal cortex, improves glutamate turnover. BNN27 exhibits neuroprotective efficacy in mouse amyotrophic lateral sclerosis (ALS) model, exhibits anti-inflammatory efficacy in experimental autoimmune encephalomyelitis (EAE) model, exhibits retinal protective efficacy in rat diabete models. BNN27 is blood-brain barrier penetrable .
    BNN27

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: